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ABSTRACT
There is conflicting evidence surrounding the extent of changes in resting energy
expenditure in cancer. This meta-analysis aimed establish the mean difference in
resting energy expenditure, as kilojoules per kilogram fat-free mass, among cancer
patients when compared to healthy control participants. The secondary aim was to
determine differences among different cancer types.
PubMed, Cochrane Library, Medline, Science Direct, Scopus, Web of Science, Wiley
Online Library, and ProQuest Central were searched from the earliest records until
March 2014. Studies were included if measured resting energy expenditure was
reported as kilojoules or kilocalories per kilogram fat-free mass in adult subjects with
cancer. Twenty seven studies were included in the meta-analysis. Fourteen studies
included both cancer (n=1453) and control (n=1145) groups. The meta-analysis
shows an average increase in resting energy expenditure of 9.66 (95% CI 3.34,
15.98) kJ/kgFFM/day in cancer patients when compared to control participants.
Heterogeneity was detected (p<0.001) which suggest variations in resting energy
expenditure among cancer types. Elevations are most noticeable in patients with
cancers of metabolically demanding organs.

Comparison of resting energy expenditure between cancer subjects and
healthy controls: A meta-analysis
INTRODUCTION
Changes in resting energy expenditure (REE) in cancer patients have been a
controversial topic in literature. Substantial evidence supports elevations in REE
during the tumour-bearing state. Elevated REE can potentially promote weight loss
which can produce suboptimal clinical outcomes and increase morbidity and
mortality risk[1]. Furthermore, elevated REE in conjunction with poor oral intake
typically seen in cancer patients serve a significant role in accelerating weight loss
and progressing to the development of malnutrition and cancer cachexia[2].
Current published findings depict inconsistencies in metabolic changes. Various
authors propose that different cancers cause varying degrees of metabolic
derangements. Fredrix et al[3] observed greater elevation of REE in lung cancer
patients than gastric-colorectal cancer patients. Cao et al[4] found elevated REE in
patients with oesophageal, gastric, pancreatic and lung cancers when compared to a
healthy control group, whereas colorectal cancer patients showed no elevation in
REE. Merli et al[5] and Xu et al[6] saw increased REE in patients with hepatocellular
carcinoma and urologic cancer, respectively. However, authors for example Fearon
et al[7] observed no significant differences in REE in colon and lung cancer patients
and Trutschnigg et al[8] reported insignificant differences in advanced cancer
patients.
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Energy expenditure is the result of metabolic activities from various body tissues and
organs. Major organs, such as the lungs and liver, are metabolically demanding and
contribute to REE due to its continuous functioning and higher energy demands to
perform metabolic processes irrespective of the body’s physical state and resting
conditions. Fat free mass (FFM) is considered to be the largest contributor to REE
suggested to provide 53-88% of REE variation[9, 10]. It would be valid to conclude
that REE is decreased if loss of FFM becomes apparent under any circumstances,
including cancer. This has not been the case as weight loss is frequently reported
and observed in cancer patients. Weight loss associated with cancer is considered
undesirable due to losses from either fat mass, FFM or both which serve important
sources of energy during periods of acute hypermetabolism[1]. It has also been
hypothesised that muscular atrophy typically observed in clinical settings is
associated with poor tolerance of cancer treatment procedures and, hence, poor
clinical outcomes[2].
Tumour-bearing is proposed to elevate energy expenditure. However, there is
uncertainty surrounding this. It has been suggested[2] that the tumour itself is
unlikely to be the direct cause of elevated energy expenditure as tumours rarely
contribute more than 5% of body weight. A plausible explanation may be that
presence of tumours can exert an indirect effect on energy expenditure. The
production of biochemical mediators stimulated by tumour growth may alter
metabolism[2]and promote the inflammatory response which could contribute to
hypermetabolism[11].
Although nutritional adequacy may be achieved to limit weight loss from FFM, the
uncertainty of the metabolic environment may impede the maintenance or restoration
of FFM[2, 12]. Identifying the extent to which REE is altered and understanding the
cancer subtypes which cause the greatest increases in REE is important from a
clinical perspective to limit anticipated weight loss as FFM and optimise clinical
outcomes. The primary aim of this study was to establish the difference in REE
between cancer patients and healthy controls. The secondary aim was to distinguish
the differences in REE between cancer subgroups. As FFM is considered to be a
large contributor to REE[9], it is appropriate to use measured REE per kg FFM. The
use of healthy control groups was deemed appropriate to use as the standard for
comparison to determine metabolic changes in cancer patients.
METHODS
Literature search
Literature searches were conducted by VN using the databases PubMed, Cochrane
Library, Medline, Science Direct, Scopus, Web of Science, Wiley Online Library, and
ProQuest Central from the earliest record to March 2014 to obtain as many
potentially relevant studies as possible. The following search terms, ‘resting energy
expenditure’, ‘resting metabolic rate’, ‘basal metabolic rate’, ‘cancer’, and ‘neoplasm’
were used. Reference lists from included studies were reviewed to obtain additional
relevant articles. The journals, Nutrition and Cancer, and Cancer and Metabolism
were also searched using the above search terms.
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Study selection
Studies in which the title included one or more of the search terms were obtained
from the literature search. The abstracts of the studies were reviewed by VN and MB
for relevance. Studies were included if REE was expressed as kilojoules (kJ) or
kilocalories (kcal) per kilogram FFM (REE/FFM), body composition was measured,
participants were adult humans with cancer, healthy control groups were defined and
used, statistical values presented as mean ± standard deviation (mean±SD) or mean
± standard error of the mean (mean±SEM), and studies were published in English.
Studies that measured REE, as REE/FFM, in cancer patients but did not include
control groups were also included. Baseline REE measurements from intervention
(pre-test/post-test) studies were included in the data set.
Data extraction
Study characteristics including the authors, source, publication year, cancer type,
and the use of control subjects were tabulated. Baseline REE, presented as kJ or
kcal per kg FFM, the number and type of subjects were collated into a Microsoft
Office Excel spreadsheet. The method used to assess REE and the method used to
assess body composition were also recorded, these were divided into more accurate
and reliable methods (Dual energy x-ray absorptiometry DEXA, total body water, or
total body potassium) and field methods (bioelectrical impedance assessment or
skinfold anthropometry) to assess study quality. The baseline REE was the
measurement prior to the cancer patients’ undergoing various treatments.
Statistical analysis
The baseline REE values and the number of participants (cancer patients and
healthy controls) were used to complete the meta-analysis conducted by MB. The
meta-analysis was conducted using STATA/IC V14 ( StataCorp LP, College Station,
Tx) using the metan command[13]. All meta-analyses were conducted using
random effects as heterogeneity was anticipated. Differences in REE amongst
cancer types were also determined through a subgroup analysis. In order to account
for the use of the same control subjects for some studies the sample sizes were
divided by the number of times the control group was used[14]. Additionally
independent subgroups within a study were considered separately in the primary
analysis[15]. In order to investigate potential confounding variables secondary
analyses were also conducted to investigate the effect of healthy versus
hospitalised/disease controls, weight losing versus weight stable cancer patients and
controls, gender, and year of publication (pre or after 2000). Results are presented
as weighted mean differences (WMD) between groups with 95% confidence intervals
(95%CI). Statistical significance of the differences between the groups is calculated
using metaregression (metareg in STATA V14.0). Study quality comparing those
studies using a more accurate and reliable measure of body composition
assessment compared with a field measure was also assessed using metagression.
RESULTS
Search results
Figure 1 shows a flowchart of the extraction process. A total of 205 abstracts were
obtained from the initial literature search, 178 abstracts were excluded on the
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following basis: 85 studies expressed REE as kJ or kcal per day body weight or body
cell mass, did not measure REE or body composition, or did not present data as
mean±SD or mean±SEM; 56 were either review articles, educational papers, poster
presentations, case reports, editorials or supplementary material; 12 studies were
published in a language other than English; 11 studies were not on the subject of
cancer; 7 studies were on animals; and 7 studies involved children. Twenty-seven
studies were considered relevant for inclusion in this review[3-8, 11, 16-35] (Table
1). Of these 27 studies, 14 studies included a healthy control group and the data
from these studies were used to generate the meta-analysis (Figure 2). Two studies
used the cancer patients as their own control.
INSERT FIGURE 1
INSERT TABLE 1
INSERT FIGURE 2
The forest plot shown in Figure 2 represents data obtained from 1453 cancer
patients and 1145 control participants. The mean difference in REE/FFM between
cancer patients and healthy controls is 9.66kJ/kgFFM/day (95% CI 3.34,15.98) which
suggests an overall increase in REE in cancer patients. The test for heterogeneity
(Chi2 =474.01 p < 0.001) suggested significant variation in REE/FFM among cancer
types, the funnel plot presented in Figure 3 shows no evidence of publication bias
but clearly emphasises the outlying value of the Wu et al study[35].
INSERT FIGURE 3
The subgroup analysis (Figure 4) represents data from 12 of the 14 studies included
in the meta-analysis. Two studies were not included in the analysis as they did not
distinguish between cancer subtypes. The subgroup analysis derived mean
differences in REE for 6 cancer types. Lung, head and neck/oesophageal, pancreatic
and urological cancers had elevations of 6.52kJ/kg FFM/day, 21.06kJ/kg FFM/day,
9.51kJ/kg FFM/day and 3.86kJ/kg FFM/day, respectively. Liver cancer illustrated the
greatest elevation of 22.68kJ/kg FFM/day. All groups were significantly elevated with
the exception of the gastric/colon cancer subgroup which showed an increase of
1.99kJ/kg/day FFM (95% CI -0.58,4.53). The head, neck and oesophageal group
elevation while high was not significant when the Wu study was included however
the funnel plot demonstrates that this study is a clear outlier (consistent with the
funnel plot in Figure 5), reanalysis without this study showed an elevation in the
head, neck and oesophageal group of 6.04 kJ/kg/day FFM (95%CI 2.27, 9.81)
indicating that REE is increased in this group. There was no evidence of publication
bias (asymmetry) in the subgroup analysis (Figure 5).
INSERT FIGURE 4
INSERT FIGURE 5
When controls were divided into healthy (WMD 14.74 95%CI 1.99,27.50
kJ/kgFFM/day) or hospitalised/diseased (WMD 4.51 95%CI 1.00,8.01) elevation in
REE in cancer patients were still significantly elevated in both groups and there was
no difference between groups P=0.264. While there was no statistically significant
difference between those identifying weight stable cancer patients and controls
(WMD 6.55 95%CI 4.21, 8.90 kJ/kg FFM/day) and those identifying weight losing
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cancer patients and controls (WMD 4.49 95%CI -0.61,9.58 kJ/kg FFM/day)
P=0.628, the elevation in the weight losing group only approached significance
P=0.084. There was no effect of year of publication when a subgroup analysis was
conducted dividing the dataset into publication year prior to (WMD 5.45 95%CI 1.54,
9.35 kJ/kg FFM/day) or after 2000 (WMD 23.51 95%CI 7.70, 39.32 kJ/kg FFM/day)
P=0.092, the wide CI for the post 2000 publications was influenced by the Wu et al
paper (without this paper the WMD for the post 2000 papers was 4.60 95%CI 3.21,
5.98 kJ/kg FFM day). Only 2 studies reported values by gender[29, 32], there was no
significant effect using meta regression (males WMD -3.33 95%CI -10.14, 3.47 kJ/kg
FFM/day and females WMD 3.75 95% CI -2.79, 10.29 kJ/kg FFM/day) P=0.179. All
studies assessed resting energy expenditure using indirect calorimetry. The study
quality assessment also showed no significant effect of body composition method
more accurate and reliable method (WMD 4.02 95%CI 0.76, 7.28 kJ/kg FFM/day)
compared with field method (WMD 12.14 95%CI 3.16, 21.11 kJ/kg FFM/day)
P=0.494.
DISCUSSION
This study sought to determine the difference in REE between cancer patients and
control subjects through summarizing data available from case-control and pretest/post-test studies. The meta-analysis derived from 16 studies suggested an 8-9%
increase in REE in cancer patients when compared to healthy control groups.
Cancer subtypes were shown in this analysis to generate different degrees of
change in REE which is consistent with the previous notion of cancer type and
tumour site affecting energy expenditure differently. While all subgroups showed an
overall increase the difference was not significant for gastric and colon cancers and
varied from 3.86 (95% CI 1.64, 6.08) kJ/kg FFM/day for Urologic cancers to
22.68(95% CI 10.80, 34.56) kJ/kg FFM/day for the single study in liver cancer.
Generally the FFM and to a lesser extent the fat mass (FM) are considered the major
contributors to the REE. The metabolic activity of the organs however cannot be
overlooked for their role in explaining variation in REE particularly if their function is
altered by malignancy. Metabolic activity can be defined as the respective processes
which occur at a cellular level to enable proper function of an organ. While a high
metabolic rate in an organ does not necessarily mean a higher metabolic rate is
generated from cancer in that tissue, in some cases metabolic activity has been
shown to be elevated in the diseased state with some major organs reportedly being
more metabolically demanding than others. The lungs are considered as highly
metabolically active organs and can utilise various substrates for normal function[36]
which may somewhat explain for the elevations. According to the subgroup analysis
(Figure 4) pancreatic cancer was also observed to generate an increase in REE. As
the pancreas possesses both endocrine and exocrine functions, it has the potential
to influence metabolism through inflammatory processes or the altered use of
substrates. It has been suggested the flux of glucose in cancer patients may be
elevated suggesting increased glucose demand[37]. Given that incomplete oxidation
of glucose is to be replaced by fat oxidation[4] this could result in an increase in
energy expenditure of 1050-1260kJ/day[37] which would correspond to
approximately 0.9kg fat loss/month. This could be a possible explanation for the
progressive weight loss often observed in cancer patients. According to the
subgroup analysis (Figure 4), REE was also significantly altered in patients with
head and neck and oesophageal cancer. Of the 3 studies reviewed, only 1 study was
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included in the analyses. Langius et al[27] reported no significant differences
between cancer patients and control participants.
Findings from Silver et al[30] were similar to those reported by Langius et al[27]
despite each of the patients in the study population being classified as either Stage 3
or 4a for cancer progression[30]. Garcia-Peris et al[20]2 reported slightly higher
metabolic rates to those of Langius et al[27] and Silver et al[30]. Interestingly,
Garcia-Peris et al[20] observed a declining trend in REE amongst cancer patients
during chemoradiotherapy which returned to pre-treatment values post treatment
with FFM largely maintained. This strongly suggests REE is unlikely to be
considerably altered in head and neck cancer patients and the post-treatment
increase in REE was largely due to unchanged FFM[20].
Four studies investigating REE in oesophageal cancer patients were included in this
review and analyses. Thomson et al[32] reported unchanged REE among patients
with oesophageal cancer whereas the results from three other studies reported
elevations[4, 34, 35]. The mean REE reported by Wu et al[35] was much higher than
those reported by other authors regarding oesophageal cancer (240.66kJ/kg/day
FFM) and other cancer types. The extent of this elevation is questionable
considering the reported mean REE from WL and WS patients were not elevated to
such a degree. However, Wu et al[35] have reported inflammatory responses
amongst cancer patients. Similarly, a number of authors[8, 11, 31]studying other
cancer types have associated elevated REE with inflammatory cytokines, such as Creactive protein (CRP), interleukins 1 and 6 (IL-1; IL-6) and tumour necrosis factor
(TNF). It has been suggested the contribution of humoral factors to hypermetabolism
and cancer cachexia may be mediated by these cytokines and promote increased
proteolysis, lipolysis and various glucose-synthesising pathways[38, 39]. This theory
could be valid and applicable with this clinical population as weight loss in healthy
individuals generally does not involve inflammatory processes. Although the
subgroup analysis concluded patients with head and neck and oesophageal cancers
experience metabolic derangements, it is important to consider the inconsistencies
of the studies used in this subgroup. Given that more studies concerning
oesophageal cancer were used in the subgroup analysis, this may bias the overall
REE for this subgroup and may not accurately reflect metabolic alterations in
patients with head and neck cancer.
Only one study included in the analyses looked at REE in cirrhotic patients with
hepatocellular carcinoma (HCC) and documented increased REE. Merli et al[5]
reported an average increase of 22.68kJ/kg/day FFM with weight-losing patients
having higher REE than weight-stable patients. Tumour stage was not considered a
major determinant of REE in cirrhotic patients with HCC as elevations in REE was
consistently observed amongst patients, and nil correlations between tumour size
and REE were made. Similar conclusions have been made in regard to other cancer
types studied by other authors[5, 21, 32, 33]. However, these conclusions are
opposed to findings from Jebb et al[26] who reported a reduction in REE in lung
cancer patients when tumour size was reduced, this study used cirrhotic controls
which may explain the differences in results. There was only one study included in
the meta-analysis (Figure 4) which studied REE in urologic cancer patients. Xu et
al[6] observed a significant increase in REE among cancer patients with kidney and
adrenal cancers reportedly causing the greatest elevations. A possible explanation
for observed elevations among HCC and urologic cancer patients may be due to its
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usual metabolic demands when in a non-diseased state. It has been proposed by
Holliday, as discussed by Weinsier et al[40], that large internal organs, such as the
liver and kidneys, could produce similar REE to that of skeletal muscle. Additionally,
when in a diseased state, the liver serves a role in inflammation and increased
energy production via gluconeogenesis which could potentially further elevate
REE[11, 28]. This may mean that some organs become more metabolically
demanding when they are cancerous and this may contribute to the increased
metabolic rate. Due to the limited number of studies for both these cancer types, it
would be difficult to derive any valid conclusions regarding changes in REE.
Studies investigating gastric and colorectal cancers consistently presented
insignificant changes in REE when compared to healthy control groups. Cao et al[4]4
found elevations in gastric cancer patients but observed unchanged REE in patients
with colorectal cancer. Other authors[3, 7, 16, 18, 19, 21, 29] saw insignificant
changes. Two studies[3, 16] reported unchanged REE among gastric-colorectal
cancer patients. However, this could be explained by the authors’ use of the same
gastric-colorectal cancer patients in both studies. This is important to consider as this
factor could also affect the findings of this present study. Two authors[16, 28]4
reported the presence of liver metastasis amongst certain patients with gastric and
colorectal cancers with mixed conclusions in relation to REE. Fredrix et a[16]
observed nil elevations in REE amongst patients with liver metastasis, whereas
Lieffers et al[28] concluded that the presence of metastasis would contribute to
elevated REE. Given that metastasis would produce a greater tumour burden, it is
valid to believe REE would be further elevated in these patients. However, this
review is unable to support this notion due to the small number of included studies
which reported the effects of metastasis on REE and its conflicting findings.
Another factor which may affect energy expenditure is gender and whether the
patients are weight stable or losing weight. Nixon et al[29] reported elevations in
REE, although not statistically significant, only in weight-losing and weight-stable
female colon cancer patients whereas male patients experienced slightly lower or
unchanged REE when compared to control participants despite no correlations being
made between REE and caloric intake. Although a secondary analysis demonstrated
there was no difference between weight losing and weight stable patients only 5
studies reported these subgroups. We also investigated the differences in gender
however only 2 studies reported results by gender and no differences were found.
The dataset as a whole contained a larger proportion of males to females (Table 1).
Although it is anticipated much of the gender difference is related to body
composition there maybe additional gender specific affects which could not be
examined in this analysis.
Limitations and recommendations
There were a limited number of patients that have been studied in each of the cancer
subtypes. Results from this study should, therefore, be interpreted with caution as
more data was available for analysis of REE in lung, gastric and colon cancers.
Available data for liver pancreatic and head and neck cancers were rather limited,
and the derived alterations in REE would lack statistical power. Some studies in this
review were published by the same authors who have utilised the same research
methodology, and the statistical analyses had several data entries contributed by the
same authors. Unique subgroups in these papers were analysed as independent
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samples[15] and the sample size was adjusted to accommodate the use of the same
control group[14], Despite this some authors may have used the same subject data
in different studies making the total number of independent subjects uncertain..
The majority of studies were published before 2000 with only 6 studies published in
the last 5 years, although we investigated this in a secondary analysis and did not
see any differences, advances in cancer treatment may have an effect on
metabolism. Table 1 also shows differences in the methodology used to assess
energy expenditure (although indirect calorimetry using a ventilated hood was the
primary method) and body composition methodology. Several studies used field
methods to assess body composition reducing the quality of the studies although this
did not have an effect on the results using meta regression.
This analysis did not consider several other cancers known to raise
REE.Haematological cancers and sarcomas have been reported to raise REE[41,
42] and these findings could serve an insightful addition to the current study. Due to
the exclusion criteria used, these and other studies which published findings about
other types of cancers not mentioned in this study were unable to be included.
Studies investigating cancer and metabolic rate often measure REE using body
weight instead of FFM which resulted in the exclusion of many studies in this
analysis. Although FFM is often regarded as a more accurate indicator of REE[9,
10], many studies did not adjust REE for FFM. Furthermore, 40% of the included
studies used the Harris-Benedict equation (HBE) to compare differences in energy
expenditure instead of healthy control groups and, therefore, were not used in the
analyses. It has been widely acknowledged the HBE tend to underestimate REE in
healthy individuals. Daly et al[43] found the use of HBE to predict energy expenditure
may not be a valid or reliable approach as it overestimated REE by 10.4% in healthy
individuals, whereas Campbell et al[44] observed underestimations between 9-23%
in critically ill and underweight male patients. Therefore, REE derived from the HBE
may not be applicable to be used as a reference for comparison in cancer patients.
Therefore, future investigations that measure REE adjusted for FFM and use healthy
control groups would be advantageous in contributing to current knowledge
regarding the cancer types discussed in this study and also other cancer types
known to generate metabolic abnormalities, such as leukaemias.
Cancer cachexia was often discussed by authors as the background for conducting
the respective studies. Yet, cachexia was not definitively identified in study patients
and patients who experienced a large amount of weight loss (>10% of usual body
weight) may have experienced varying degrees of cachexia. As cachexia greatly
involves the inflammatory response and altered energy metabolism, REE would
subsequently increase. If this was the case, the measured REE of patients who
experienced large amounts of weight loss would skew the results reported by the
authors and the results of this meta-analysis.
In conclusion, this meta-analysis supports current evidence of elevated REE in
cancer patients when compared to healthy control participants with an observed 89% increase. Additionally, this study emphasised the heterogeneity observed among
cancer types in REE. Due to the exclusion of many studies, not all cancer types were
included in the meta-analysis as the results were not expressed as REE based on
FFM. Further investigation of alterations in energy expenditure based on FFM can
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assist to clarify previous findings, in particular for cancer types not included in this
review, and to provide renewed data. New data will build the current evidence base
for the provision of additional nutrition support to compensate for elevated energy
consumption in metastatic cancer patients[14].
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Table 1. Characteristics of studies investigating the alterations in REE per kg FFM in cancer patients.
Source

Study sample number, M/F, Mean
age

Cao et al. 20104

714 newly detected cancer
patients.
150 oesophageal, 154 gastric,
148 colorectal, 128 pancreatic,
134 NSCLC
M/F = 477/237, Age 56

642 control subjects
M/F = 445/195
Age 55.4

21 pancreatic cancer patients.
M/F = 14/7
Age 57

16 control subjects
M/F = 11/5
Age 55

Falconer et al.
199411

Fearon et al.
19887

20 lung cancer patients.
M/F = -, Age 60
38 colon cancer patients
M/F=-, Age 64.5

Control sample number,
M/F, Mean age

22 control subjects (nonneoplastic diseases).
M/F = -, Age 58.8

Study design

Case control.
Cancer patients & control participants
recruited from hospital setting. Cancer
patients were adults, afebrile, nil organ
dysfunction, nil cancer treatment, nil
endocrine abnormalities, nil dialysis/fluid
replacement.
Case control.
Patients with newly detected tumours. Cancer
patients received nil treatment, afebrile, nil
infection, nil cholangitis one month prior, nil
jaundice. Patients had stage 2 (n=7), stage 3
(n=8) & stage 4 (n=6) using Union
Internationale Contre le Cancer TNM
classification.
Control participants admitted for minor
elective surgical procedures.
Case control.
Lung cancer patients with nil previous
treatment two months prior. Stage 2 (n=9) &
stage 3 (n=11) using WHO classification.
Colon cancer patients studied prior to
laparotomy. Stage B (n=16), stage C (n=11),
stage D (n=10) using Dukes’ classification.
Control participants had non-neoplastic
disease.

Methodology used to measure REE & FFM

REE measured via IC using ventilated hood system
in standard resting conditions (>3hours
postprandial, 30 minute bed rest).
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Subjective study summary

FFM determined using formula (1.106xECF+1.521x
ICF). ECF, ICF & total water determined using
multi-BIA.

Cancer patients (all subgroups) had
higher REE than controls. WL cancer
patients had higher REE than WS and
control patients. Stage IV patients had
higher REE than Stages I-III. Cancer
type, pathological stage, duration of
disease responsible for REE.

FM determined using formula (BW-FFM).
REE via IC using a ventilated hood system after
overnight fast in resting conditions.

Pancreatic cancer patients had higher
REE than controls.

FFM measured via BIA.

REE via IC with a rigid canopy (sensitive
paramagnetic oxygen analyser) & an IR carbon
dioxide analyser. Patients were fasted overnight &
at rest for 30 minutes.
FFM derived from measurements of total body
water.

Nil significant difference in REE
between both cancer groups and
controls.

Nguyen
Fredrix et al.
199134

104 gastric/colorectal patients
(25/104 had liver metastases;
41/104 had stages 1 and 2; 63/104
had stages 3 & 4).
M/F = 54/50, Age 70

72 control subjects
32 GI diseases
M/F GI = 20/12, Age 64
40 healthy
M/F = 18/22 Age 65

Case control.
Patients with newly detected cancer & nil
previous treatment.
Control participants with non-malignant GI
diseases.

REE calculated using abbreviated Weir formula.
Ventilated hood system used to measure gas
exchange. Cancer patients were fasted overnight 7
after >30minute bed rest. REEs of cancer patients
& some control participants measured during
hospital stay. REE of remaining control participants
measured on an outpatient basis.

REE not elevated in GCR- cancer
patients compared to controls.
Nil association between increased REE
and cancer stage.
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FFM estimated using BIA & calculated using
formula of Segal.
Fredrix et al.
1991

3

Fredrix et al.
1997

35

Fredrix et al.
1991

36

104 gastric/colorectal patients
M/F = 54/50, Age 70
47 NSCLC patients
M/F = 43/4, Age 66

53 NSCLC patients (pre-surgery); 39
patients (post-surgery)
M/F no recurrence = 20/10
M/F tumour recurrence = 8/1. Age
65.5

30 NSCLC patients
M/F = 27/3, Age 65
104 gastric/colorectal patients
M/F = 54/50, Age70

40 healthy controls
M/F = 18/22
Age 65

Patients with newly detected cancer & nil
previous treatment.
Control participants had nil conditions which
may affect metabolic rate.

NSCLC patients acted as
their own controls

Pre-test/Post-test.
Cancer patients had newly detected primary
NSCLC. Nil previous treatment, afebrile, nil
high doses of steroids, nil severe endocrine
abnormalities.

Nil

Post-test.
Cancer patients had newly detected NSCLC &
had nil previous treatment.

REE via IC using ventilated hood system &
calculated using abbreviated Weir formula.
Patients were fasted overnight & were rested >30
minutes.
FFM estimated via BIA & calculated using formula
of Segal. BIA was used in only half of GCR patients
due to nil equipment availability at beginning of
study.
REE measured by IC using ventilated hood system
after overnight fast & were rested for >20 minutes.
Post resection REE measured on an outpatient
basis. REE calculated using abbreviated Weir
formula.

Lung cancer patients have elevated
REE, while GCR cancer patients have
unchanged REE.
Surgical resection normalises REE in
lung cancer patients.
Cancer type contributes to REE.

REE reduced slightly after surgery in
hyper-metabolic patients.

FFM estimate using BIA. FFM = total body
water/0.73.
REE measured prior to patients undergoing
surgery. REE also measured 3, 6 & 12 months post
resection.
REE measured by IC using ventilated hood system
after overnight fast & 30 minute rest period. REE
calculated using abbreviated Weir formula.
FFM estimated using BIA & calculated using
formula of Segal.

REE elevated in lung cancer patients.
Strong correlation between increased
REE and weight loss in lung cancer
patients.

Nguyen
Fredrix et al.
199037

Garcia-Peris et
al. 200522

Hansell et al.
198638

39
22 GCR patients
M/F = 13/9, Age 68
17 lung patients
M/F = 16/1, Age 68

40 healthy controls
M/F = 18/22
Age 65

18 H&N patients (stages 3 & 4)
M/F = 15/3, Age 57

Nil

Case control.
Cancer patients had newly detected tumours
& had nil previous treatment.
Control participants were healthy. Nil health
conditions reported.
Pre-test/post-test.
H&N cancer patients (stage 3 & 4) without
distant metastasis. Nine patients had previous
radical surgery. All patients treated with
radiotherapy & concurrent chemotherapy.

24 colon
Tumour-bearing
M/F = 5/4, Age 68
Tumour-free
M/F = 8/7, Age 65

Each patient acted as
his/her own control

Pre-test/post-test.
Cancer patients had nil infection, nil
treatment.
Tumour-bearing patients had hepatic
metastasis. Tumour-free patients showed nil
hepatic metastasis.

REE measured via IC using ventilated hood system
after overnight fast & rested for >30 minutes.
BIA used to measure body composition. FFM
estimated using formula of Segal.

REE measured via IC (open circuit calorimeter)
after overnight fast. REE calculated using Weir
formula.
Tetrapolar, single frequency Holtain BC analyser
(BIA) to measure body composition. FFM
calculated using software provided by
manufacturer.
REE & FFM measured before treatment, at weeks
2, 4 & 6, and 2 weeks post treatment.
REE measured using IC with rigid canopy after
overnight fast & 30 minute rest period. REE
calculated using Weir’s formula.

REE elevated in lung cancer patients.
Tumour type affects REE. Reduced EI in
GCR patients explained weight loss as
REE is unchanged. Increased REE and
low EI explained weight loss.
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REE decreases during chemotherapy
but normalises at the end of treatment.
Effects of treatment may contribute to
reduced REE. FFM increased which may
explain increased REE and weight loss.

REE between tumour-free and tumourbearing patients showed nil significant
difference. Colon cancer had nil effect
on REE.

FFM derived from measurement of total body
water assuming lean tissue contains 73% water
(urine collected 3 & 4 hours after tritium
injections).
REE & FFM measured pre-operatively and postoperatively.

Hansell et al.
1986

14

84 patients
51 colorectal
M/F = 29/22, Age 67
22 gastric
M/F = 14/8, Age 67
11 bronchial
M/F = 9/2, Age 61

Nil

Case series.
Cancer patients had nil infection, nil
treatment.

REE measured via IC with rigid canopy after
overnight fast & after 30 minute rest period. REE
calculated using Weir formula.
FFM derived from measurement of total body
water assuming lean tissue contains 73% water
(urine collected 3 & 4 hours after tritium
injections).

Nil significant difference in REE
between cancer groups.
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Hansell et al.
198639

98 patients
(91 GCR & 7 bronchial)
56 WS
M/F = 40/16, Age 66
42 WL
M/F = 23/19, Age 65

38 control patients
22 WS
M/F = 6/16, Age 62
16 WL
M/F = 8/8, Age 63

Case control.
Cancer patients had nil infection & nil prior
treatments.
Control patients had non-malignant diseases
(peptic ulcerations, choleithiasis, others).
Liver metastasis present in 11 WS patients & 8
WL patients.

Harvie et al.
200540

Harvie et al.
200441

41 patients
19 NSCLC (Stage 3 or 4)
M/F = 15/4, Age 59
12 metastatic melanoma
M/F = 9/3, Age 54
10 metastatic breast
M/F = 0/10, Age 56

Healthy control
participants also recruited.
Number of participants
not reported & only REE
measured in this group.

17 female breast cancer patients,
Age 46

21 controls, Age 45

Pre-test/Post test.
Cancer patients received nil treatment within
previous 3 months.
Control participants recruited by hospital staff.

28 small cell lung cancer
18 responders
M/F = 12/6, Age 63
10 non-responders
M/F = 8/2, Age 60

FFM derived from measurement of total body
water assuming lean tissue contains 73% water
(urine collected 3 & 4 hours after tritium
injections).

REE via IC under standardised conditions. REE also
measured in control participants but not reported.

Nil significant difference in REE
between cancer patients and controls.
Tumour type had no influence on REE.
Patients’ metabolic response to nonmalignant illness may determine
changes in REE.

16

REE elevated in NSCLC patients and
normal in breast cancer and melanoma
patients.

FFM determined using total body potassium
(NE8108 shadow shield whole body monitor).
Patients seen prior to commencing chemotherapy,
prior to 2nd chemotherapy cycle & 1 month post
completion of chemotherapy.

Pre-test/post-test.
Cancer patients with newly diagnosed invasive
breast cancer recruited by telephone prior to
commencing adjuvant chemotherapy & within
3 weeks of breast surgery. Patients received
nil previous treatment, had nil endocrine
abnormalities or psychiatric morbidity.

Jebb et al.
199442

REE measured via IC with rigid canopy after
overnight fast & after 30 minute rest period. REE
calculated using Weir formula.

Nil

Healthy control participants recruited by
hospital staff.
Pre-test/post-test.
SCLC patients recruited over a 12 month
period in outpatient clinics. Patients received
nil prior treatment.

REE via IC using open circuit ventilated hood
system after overnight fast & 20 minute rest
period. REE calculated using Weir formula.

Higher REE in breast cancer patients,
may be due to surgery.

FFM measured using total body impedance (total
body water) via tetrapolar impedance meter.
REE measured in both groups but results of control
group not reported.
REE measured using portable IC after overnight
past & 30 minute rest period. REE calculated using
equation of Elia & Livesey.
FFM determined using LUNAR-DPX scanner.
REE & body composition measured at baseline & 1
month post-treatment.

Reduction in tumour mass resulted in
reductions in REE independent of body
composition. Tumours have the ability
to increase REE.
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Langius et al.
201220

71 H&N cancer patients
M/F = 45/26, Age 65

40 healthy controls
M/F = 20/20, Age 59

Pre-test/post-test, observational.
Cancer patients receiving primary or
postoperative radiotherapy.
Nil patients with distant metastasis,
thyroid/inflammatory diseases, receiving
concurrent chemotherapy or receiving 2nd
dose of radiotherapy.

Lieffers et al.
200929

Merli et al.
19925

Nixon et al.
198816

18 colorectal cancer patients
Age 60

12 cirrhotic patients with HCC
M/F = 6/6, Age 64

98 patients
46 colon
M/F = 30/15, Age 58.5
52 NSCLC
M/F = 27/11, Age 57.5

Nil

Healthy control participants recruited through
advertisement on internet & in
hospital/university campus.
Case series.
Cancer patients recruited from the Cross
Cancer Institute (Canada).

12 cirrhotic patients
without HCC
M/F = 6/6, Age 55

104 controls, 60 healthy
M/F = 17/43, Age ≥40
5 anorexia nervosa
9 non-neoplastic GI
disorders
12 protein-energy
malnutrition
9 chronic lung disease

Case control.

REE measured via IC prior to treatment, after 3
weeks of treatment, at the end of treatment, and
12 weeks after completion of treatment. Patients
& participants were at complete rest for 30
minutes & REE calculated using Weir equation.

REE of cancer patients pre-treatment was
compared to REE of control participants.
REE via IC (after 12 hour fast & 30 minute rest
period. REE calculated using Weir equation.
FFM measured via dual x-ray absorptiometry scan.

Cancer patients had nil prior treatment.
Control patients without HCC selected based
on similar body weight & height to cancer
patients.

FFM calculated using the method of Durnin &
Womersley via skin fold tests (biceps, tricepts,
suprailiac & subscapular).

Case control.

REE measured using direct gradient-layer wholebody calorimetry after overnight fast & 15 minute
rest period. Chemotherapy patients studied prior
to commencing chemotherapy cycle.

Control participants divided into 5 groups.

17

FFM assessed using single-frequency BIA. FFM
calculated using validated equation of Kyle.

REE measured using a metabolic-measurement
cart with a canopy system after overnight fast & 30
minute rest period.

Cancer patients admitted to Emory Clinical
Research Facility or the Emory Oncology
Ward. Patients had nil surgery >21 days prior,
nil acute/chronic diseases, nil
alcohol/tranquiliser abuse.

REE didn't differ to controls before
treatment but decreased during and
after treatment.

FFM derived from body weight & skin fold
measurements. FFM calculated using Durnin &
Womersley method.

Metastatic disease and organomegaly
can elevate REE.
Variances in REE depend on types of
FFM (i.e. major organs vs. skeletal
muscle).

REE increased in cirrhotic patients with
HCC. Tumour stage not determinant of
REE.

REE didn't differ between cancer types
and controls.
REE elevated in WL female lung & colon
cancer patients.
REE generally higher in WL cancer
patients.

Nguyen
Silver et al.
200721

17 Stage III & IVa H&N cancer
patients
M/F = 15/2, Age 59

Nil

Staal-van den
Brekel et al.
199417

100 lung patients
M/F = 82/18, Age 65

Nil

Thomson et al.
199023

14 patients with oesophageal
cancer
M/F = 9/5, Age 54.5

Trutschnigg et
al. 20138

Vaisman et al.
201218

Pre-test/post-test.
Cancer patients recruited from the VanderbiltIngram Cancer Center. Patients studied prior
to commencing radiotherapy & 1 month post
treatment.
Case series.
Cancer patients had nil previous treatment, nil
steroid treatment, nil severe endocrine
abnormalities, afebrile.

17 controls (benign
disease) M/F = 11/6
Age 56

8 female advanced cancer patients
over 65yrs (cholangiocarcinoma,
colon, liver, pancreatic, NSCLC)
M/F = 0/8, Age 73

11 healthy female controls
over 65yrs
M/F = 0/11, Age76

45 pancreatic cancer patients (15
post-operative; 30 advanced)
M/F =-, Age 57

75 healthy controls
Age 57

Case control.
Cancer patients admitted to King Edward the
VIII Hospital. Patients were studied prior to
surgery.
Control participants admitted for minor
procedures.
Case control.
Patients & controls recruited through
advertisement & physician referrals from
Royal Victoria Hospital & the HepatoPancreato-Biliary Cancer Centre of the McGill
University Health Centre.
Case control, cross sectional study.

REE via IC with open-circuit system after an 8-hour
fast & 60 minute rest period.

Elevated REE 1 month post
chemoradiation.
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FFM assessed using dual-energy x-ray
absorptiometry.
REE measured by IC using ventilated hood system
after an overnight fast at complete rest.
FFM assessed using single frequency BIA &
calculated using patient specific regression
equation (FFM = 8.9+0.5x[height2/resistance]).
REE via IC after overnight fast & calculated using
modified equations from other authors.

Central tumour localisation and
inflammation contribute to increased
REE. WL due to increased REE and
decreased intake. Higher REE in WL
patients.

Tumour had little effect on REE.
Changes in REE were secondary to
changes in body composition.

FFM derived from skin fold thickness using the
tables from Durnin & Womersley.

REE measured using IC & calculated using the Weir
equation.

REE not significantly different between
groups.

FFM determined using dual-energy x-ray
absorptiometry.
REE measured by IC after overnight fast and 20
minute rest period.
FFM measured via dual-energy x-ray
absorptiometry.

REE not significantly different between
groups. Resection of tumour does not
influence REE.
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Weston et al.
198924

Wu et al. 201325

Xu et al. 20126

30 cancer patients (gastrooesophageal, colorectal, other GI
cancer).
M/F WS = 15/5, Age 64
M/F WL = 5/5, Age 71

7 benign controls
M/F = 3/4
Age 66

56 male oesophageal cancer
patients
M/F = 56/0, Age 61

30 healthy controls
Age 62

122 urologic cancer patients
74 kidney, 31 bladder, 17 adrenal
M/F = 72/50, Age 55

Case control.
Cancer & control patients studied prior to
surgery.
Control patients had non-malignant
gastrointestinal disease.

131 non malignant
controls
M/F = 75/56, Age 54

Case control.
Cancer patients recruited from Xin Hua
Hospital. Patients had nil previous treatment,
afebrile, nil severe endocrine abnormalities,
nil dialysis/fluid replacement.

Case control.
Cancer patients & control participants
recruited from Zhongshan Hosptial, Fudan
University at time of primary diagnoses.

REE via IC after an 8 hour overnight fast &
calculated using Weir formula.
FFM derived from total body potassium &
calculated using values derived by other authors.

REE measured via open-circuit IC via ventilated
hood system 3 hours post-prandial and 30 minute
bed rest. REE calculated using Weir equation.

WL patients had higher REE but nil
significant difference in REE between
groups. GI cancer patients have nil
changes in REE.
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REE of cancer patients significantly
increased compared to controls.

FFM determined using four-lead BIA.

REE via IC using ventilated hood system &
calculated using equation: mREE=5.50xVO2
+1.76xVCO2

REE significantly elevated in cancer
patients. REE can be influenced by
tumour type and tumour stage.

FFM determined using multi-BIA from ICF & ECF,
using equation: FFM=1.106xECF+1.521xICF.
REE & FFM measured pre-operatively.

REE, resting energy expenditure; FFM, fat free mass; NSCLC, non small cell lung carcinoma; M, male; F, female; -, gender distribution unspecified; WS, weight stable; WL, weight loss; GCR, gastric-colorectal; EI,
energy intake; H&N , head & neck; HCC, hepatocellular carcinoma; IC, indirect calorimetry; BIA, bioelectrical impedance analysis.
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Study
ID

%
Weight

WMD (95% CI)

Hansell et al 1986
Hansell et al 1986
Fearon et al 1988
Fearon et al 1988
Fearon et al 1988
Fearon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Weston et al 1989
Weston et al 1989
Thomson et al 1990
Thomson et al 1990
Fredrix et al 1991
Fredrix et al 1991
Merli et al 1992
Falconer et al 1994
Cao et al 2010
Vaisman et al 2011
Langius 2012
Xu et al 2012
Trutschnigg et al 2013
Wu et al 2013
Overall (I-squared = 94.4%, p = 0.000)

5.04 (-4.27, 14.35)
3.96
0.84 (-7.39, 9.07)
4.04
3.00 (-13.86, 19.86)
3.26
11.00 (0.45, 21.55)
3.85
13.00 (-5.49, 31.49)
3.10
1.00 (-7.77, 9.77)
4.00
0.00 (-14.93, 14.93)
3.45
7.05 (-7.29, 21.39)
3.50
-14.11 (-27.59, -0.63) 3.59
3.02 (-26.30, 32.34)
2.15
-5.04 (-14.76, 4.68)
3.92
0.00 (-10.13, 10.14)
3.89
1.01 (-10.22, 12.25)
3.79
6.04 (-4.83, 16.92)
3.83
-2.50 (-31.95, 26.95)
2.14
13.50 (-17.22, 44.22)
2.05
-1.00 (-15.34, 13.34)
3.50
4.00 (-13.55, 21.55)
3.19
0.84 (-4.29, 5.97)
4.24
16.80 (10.11, 23.49)
4.15
22.68 (10.80, 34.56)
3.74
28.98 (12.74, 45.22)
3.32
5.25 (3.35, 7.15)
4.35
5.04 (-1.40, 11.48)
4.16
1.68 (-5.95, 9.31)
4.08
3.86 (1.64, 6.08)
4.34
9.24 (-14.80, 33.28)
2.58
117.18 (106.66, 127.70) 3.86
9.36 (3.34, 15.39)
100.00

NOTE: Weights are from random effects analysis
-128

0

128

Figure 1. Mean REE/FFM is significantly higher in cancer patients. The size of the
shaded squares is proportional to the weight of each study. The horizontal lines
represent 95% CI. Multiple entries from the same paper represent figures presented
divided by cancer subtype, weight losing/weight stable and/or sex.
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Study
ID
1
Fearon et al 1988
Fearon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Fredrix et al 1991
Cao et al 2010
Subtotal (I-squared = 60.2%, p = 0.014)
.
2
Fearon et al 1988
Fearon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Nixon et al 1988
Fredrix et al 1991
Cao et al 2010
Cao et al 2010
Subtotal (I-squared = 31.4%, p = 0.167)
.
3
Weston et al 1989
Weston et al 1989
Thomson et al 1990
Thomson et al 1990
Cao et al 2010
Langius 2012
Subtotal (I-squared = 0.0%, p = 0.494)
.
4
Merli et al 1992
Subtotal (I-squared = .%, p = .)
.
5
Falconer et al 1994
Cao et al 2010
Vaisman et al 2011
Subtotal (I-squared = 74.3%, p = 0.020)
.
Overall (I-squared = 59.0%, p = 0.000)

WMD (95% CI)

%
Weight

3.00 (-13.86, 19.86)
11.00 (0.45, 21.55)
0.00 (-14.93, 14.93)
7.05 (-7.29, 21.39)
-5.04 (-14.76, 4.68)
0.00 (-10.13, 10.14)
16.80 (10.11, 23.49)
6.72 (3.51, 9.93)
5.85 (0.71, 10.98)

1.69
3.33
2.05
2.18
3.68
3.50
5.30
7.65
29.39

13.00 (-5.49, 31.49)
1.00 (-7.77, 9.77)
-14.11 (-27.59, -0.63)
3.02 (-26.30, 32.34)
1.01 (-10.22, 12.25)
6.04 (-4.83, 16.92)
0.84 (-4.29, 5.97)
5.29 (1.33, 9.25)
-0.00 (-3.31, 3.31)
1.70 (-1.29, 4.69)

1.46
4.13
2.39
0.64
3.08
3.21
6.35
7.16
7.59
35.99

-2.50 (-31.95, 26.95)
13.50 (-17.22, 44.22)
-1.00 (-15.34, 13.34)
4.00 (-13.55, 21.55)
8.69 (4.73, 12.66)
1.68 (-5.95, 9.31)
6.60 (3.29, 9.91)

0.64
0.59
2.18
1.59
7.15
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NOTE: Weights are from random effects analysis
-45.2

0

45.2

Figure 2. Subgroup analysis showing elevations in REE for each cancer subtype. The
size of the shaded squares is proportional to the weight of each study. The horizontal
lines represent 95% CI. 1Lung; 2Gastric/colon; 3Head, neck and oesophageal; 4Liver;
5Pancreatic.

Multiple entries from the same paper represent figures presented divided

by cancer subtype, weight losing/weight stable and/or sex.
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Figure 3 Funnel Plot
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Figure 4

REE cancer subgroups compared with control
Study
ID

WMD (95% CI)

%
Weight

3.00 (-16.50, 22.50)
11.00 (-0.26, 22.26)
0.00 (-19.48, 19.48)
7.05 (-8.59, 22.69)
-5.04 (-17.88, 7.80)
0.00 (-11.25, 11.26)
16.80 (9.12, 24.48)
6.72 (2.56, 10.88)
6.52 (1.51, 11.53)

2.93
3.70
2.93
3.30
3.56
3.70
3.98
4.18
28.27

13.00 (-7.93, 33.93)
1.00 (-8.60, 10.60)
-14.11 (-32.50, 4.28)
3.02 (-26.95, 33.00)
1.01 (-13.02, 15.04)
6.04 (-5.88, 17.96)
0.84 (-5.53, 7.21)
5.29 (0.53, 10.05)
-0.00 (-4.24, 4.24)
1.97 (-0.58, 4.53)

2.79
3.84
3.03
2.05
3.45
3.64
4.07
4.15
4.17
31.20

-2.50 (-43.97, 38.97)
13.50 (-28.88, 55.88)
-1.00 (-15.34, 13.34)
4.00 (-13.55, 21.55)
8.69 (3.93, 13.46)
1.68 (-5.95, 9.31)
117.18 (106.66, 127.70)
21.06 (-12.96, 55.08)

1.39
1.35
3.42
3.11
4.15
3.99
3.76
21.17

22.68 (10.80, 34.56)
22.68 (10.80, 34.56)

3.65
3.65

28.98 (12.74, 45.22)
5.67 (1.47, 9.87)
5.04 (-1.40, 11.48)
9.51 (1.06, 17.96)

3.24
4.18
4.06
11.48

3.86 (1.64, 6.08)
3.86 (1.64, 6.08)

4.24
4.24

9.49 (3.53, 15.45)

100.00

Lung

1
Fearon 1988
Fearon 1988
Nixon 1988
Nixon 1988
Nixon 1988
Nixon 1988
Fredrix 1991
Cao 2010
Subtotal (I-squared = 42.9%, p = 0.093)
.
2
Fearon 1988
Fearon 1988
Nixon 1988
Nixon 1988
Nixon 1988
Nixon 1988
Fredrix 1991
Cao 2010
Cao 2010
Subtotal (I-squared = 0.0%, p = 0.501)
.
3
Weston 1989
Weston 1989
Thomson 1990
Thomson 1990
Cao 2010
Langius 2012
Wu 2013
Subtotal (I-squared = 98.4%, p = 0.000)
.
4
Merli 1992
Subtotal (I-squared = .%, p = .)
.
5
Falconer 1994
Cao 2010
Vaisman 2011
Subtotal (I-squared = 74.1%, p = 0.021)
.
6
Xu 2012
Subtotal (I-squared = .%, p = .)
.
Overall (I-squared = 94.2%, p = 0.000)

Gastric/Colon

Head/Neck/Oesophageal

Liver

Pancreas

Urologic

NOTE: Weights are from random effects analysis
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WMD weighted mean difference, se standard error, 1-6, indicates the different cancer types as
labelled.
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Figure 5 Funnel plot for subgroup analysis
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